Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
To evaluate the use of ibritumomab tiuxetan (Zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from family donor's peripheral blood.
Non-Hodgkin Lymphoma
DRUG: Ibritumomab Tiuxetan (Zevalin)
progression-free survival, 12 months
safety (toxicity, transplantation- and graft-related mortality), 36 months|response to treatment according to the Cheson's criteria (Cheson B, et al. JCO 25, 570, 2007)., 36 months|overall survival, 36 months|relapse rate, 36 months|acute and chronic Graft-versus-Host Disease, 36 months|haematological and immunological reconstitution, and chimerism., Post transplantation. Once weekly until day +100 and every 2 weeks from day +100.|the impact of Complete Clinical Response, determined by flow cytometry and PET, on progression-free survival, 36 months
To evaluate the use of ibritumomab tiuxetan (Zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from family donor's peripheral blood.